个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Baseline C-reactive protein predicts efficacy of the first-line immune checkpoint inhibitors plus chemotherapy in advanced lung squamous cell carcinoma: a retrospective, multicenter study

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Xinlong Zheng[1] ; Longfeng Zhang[1] ; Lin Wu[3] ; Jun Zhao[4] ; Jianguo Sun[5] ; Yong Fang[6] ; Jin Zhou[7] ; Qian Chu[8] ; Yihong Shen[9] ; Zhenzhou Yang[10] ; Lijin Chen[11] ; Meijuan Huang[12] ; Xiaoyan Lin[13] ; Zhenhua Liu[14] ; Peng Shen[15] ; Zhijie Wang[16] ; Xin Wang[17] ; Huijuan Wang[18] ; Zhengbo Han[19] ; Anwen Liu[20] ; Hongmei Zhang[21] ; Feng Ye[22] ; Wen Gao[23] ; Fang Wu[24] ; Zhengbo Song[25] ; Shengchi Chen[26] ; Chenzhi Zhou[27] ; Qian Wang[28] ; Chunwei Xu[29] ; Dingzhi Huang[30] ; Xiaobin Zheng[1] ; Qian Miao[1] ; Kan Jiang[1] ; Yiquan Xu[1] ; Shiwen Wu[1] ; Haibo Wang[1] ; Qiuyu Zhang[31] ; Shanshan Yang[1] ; Yujing Li[1] ; Sihui Chen[1] ; Gen Lin[1,2,32] ;
机构： [1]Department of Thoracic Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China [2]Fujian Key Laboratory of Advanced Technology for Cancer Screening and Early Diagnosis, Fuzhou, China [3]The Second Department of Thoracic Oncology, the Afliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital, Changsha, China [4]Department of Thoracic Medical Oncology, Peking University Cancer Hospital and Institute, Beijing, China [5]Cancer Institute, Xinqiao Hospital, Army Medical University, Chongqing, China [6]Department of Medical Oncology, Sir Run Run Shaw Hospital, Zhejiang University, Zhejiang, China [7]School of Medicine, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, Sichuan, China [8]Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China [9]Department of Respiratory Diseases, The First Afliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China [10]Department of Cancer Center, The Second Afliated Hospital, Chongqing Medical University, Chongqing, China [11]Department of Oncology, Afliated Quanzhou First Hospital of Fujian Medical University, Quanzhou, China [12]Department of Thoracic Oncology, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China [13]Department of Oncology, Fujian Medical University Union Hospital, Fuzhou, China [14]Department of Medical Oncology, Provincial Clinical College, Fujian Medical University, Fujian provincial hospital, Fuzhou, China [15]Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China [16]Medical Oncology Department, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences, and Peking Union Medical College, Beijing, China [17]Department of Oncology, Zhongshan Hospital of Xiamen University, Xiamen, China [18]Department of Respiratory Medicine, the Afliated Cancer Hospital of Zhengzhou University, Zhengzhou, China [19]Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China [20]Department of Oncology, The Second Afliated Hospital of Nanchang University, Nanchang, China [21]Department of Oncology, Xijing Hospital, Airforce Military Medical University, Xian, Shanxi, China [22]Department of Medical Oncology, Cancer Hospital, The First Afliated Hospital of Xiamen University, School of Medicine, Xiamen University, Teaching Hospital of Fujian Medical University, Xiamen, China [23]Department of Medical Oncology, The First Afliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China [24]Department of Oncology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China [25]Department of Clinical Trial, Cancer Hospital of the University of Chinese Academy of Sciences, Hangzhou, Zhejiang, China [26]Department of Oncology, Nanping First Hospital Afliated to Fujian Medical University, Nanping, China [27]Respiratory Medicine Department, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Afliated Hospital of Guangzhou Medical University, Guangzhou, China [28]Department of Respiratory Medicine, Afliated Hospital of Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China [29]Department of Respiratory Medicine, Afliated Jinling Hospital, Medical School of Nanjing University Nanjing, Nanjing, Jiangsu, China [30]Department of Thoracic Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China [31]Institute of Immunotherapy, Fujian Medical University, Fuzhou, China [32]Interdisciplinary Institute for Medical Engineering, Fuzhou University, Fuzhou, China
出处：
DOI： 10.1186/s12885-023-11737-x
ISSN：

关键词： Lung squamous cell carcinoma Immune checkpoint inhibitors C-reactive protein Predictive biomarker

摘要：
To investigate the predictive value of baseline C-reactive protein (CRP) levels on the efficacy of chemotherapy plus immune checkpoint inhibitors (ICI) in patients with advanced lung squamous cell carcinoma (LSCC).In this retrospective multicenter study spanning from January 2016 to December 2020, advanced LSCC patients initially treated with chemotherapy or a combination of chemotherapy and ICI were categorized into normal and elevated CRP subgroups. The relationship between CRP levels and treatment outcomes was analyzed using multivariate Cox proportional hazards models and multivariate logistic regression, focusing primarily on the progression-free survival (PFS) endpoint, and secondarily on overall survival (OS) and objective response rate (ORR) endpoints. Survival curves were generated using the Kaplan-Meier method, with the log-rank test used for comparison between groups.Of the 245 patients evaluated, the 105 who received a combination of chemotherapy and ICI with elevated baseline CRP levels exhibited a significant reduction in PFS (median 6.5 months vs. 11.8 months, HR, 1.78; 95% CI: 1.12-2.81; p = 0.013) compared to those with normal CRP levels. Elevated CRP was identified as an independent risk factor for poor PFS through multivariate-adjusted analysis. However, among the 140 patients receiving chemotherapy alone, baseline CRP levels did not significantly influence PFS. Furthermore, within the combination therapy group, there was a notable decrease in the ORR (51% vs. 71%, p = 0.035), coupled with a significantly shorter OS (median 20.9 months vs. 31.5 months, HR, 2.24; 95% CI: 1.13-4.44; p = 0.033).In patients with advanced LSCC, elevated baseline CRP levels were identified as an independent predictive factor for the efficacy of combination therapy with chemotherapy and ICI, but not in chemotherapy alone. This suggests that CRP may be a valuable biomarker for guiding treatment strategies.© 2023. The Author(s).

基金：
National Natural Science Foundation of China [grant number 82372954], National Natural Science Foundation of China [grant number 82072565], Fujian Provincial Health Systemic Innovation Project [grant number 2020CXA010], the Fujian provincial health technology project [grant number 2020QNA014], Scientifc and technological innovation joint capital projects of Fujian Province [grant number 2020Y9038], and Beijing Xisike Clinical Oncology Research Foundation [grant number Y-2019AZZD-0386].
语种：
外文
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2023]版：
大类 | 2 区 医学
小类 | 3 区 肿瘤学
最新[2023]版：
大类 | 2 区 医学
小类 | 3 区 肿瘤学
JCR分区：
出版当年[2023]版：
Q2 ONCOLOGY
最新[2023]版：
Q2 ONCOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2022版]

第一作者：
第一作者机构： [1]Department of Thoracic Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China
共同第一作者：
通讯作者：
通讯机构： [1]Department of Thoracic Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China [2]Fujian Key Laboratory of Advanced Technology for Cancer Screening and Early Diagnosis, Fuzhou, China [32]Interdisciplinary Institute for Medical Engineering, Fuzhou University, Fuzhou, China
推荐引用方式(GB/T 7714)：
Xinlong Zheng,Longfeng Zhang,Lin Wu,et al.Baseline C-reactive protein predicts efficacy of the first-line immune checkpoint inhibitors plus chemotherapy in advanced lung squamous cell carcinoma: a retrospective, multicenter study[J].BMC CANCER.2023,23(1):doi:10.1186/s12885-023-11737-x.
APA：
Xinlong Zheng,Longfeng Zhang,Lin Wu,Jun Zhao,Jianguo Sun...&Gen Lin.(2023).Baseline C-reactive protein predicts efficacy of the first-line immune checkpoint inhibitors plus chemotherapy in advanced lung squamous cell carcinoma: a retrospective, multicenter study.BMC CANCER,23,(1)
MLA：
Xinlong Zheng,et al."Baseline C-reactive protein predicts efficacy of the first-line immune checkpoint inhibitors plus chemotherapy in advanced lung squamous cell carcinoma: a retrospective, multicenter study".BMC CANCER 23..1(2023)

相关文献

[1]Association between pretreatment C-reactive protein level and survival in non-small cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis [2]Advances in Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma. [3]The prognostic value of the preoperative c-reactive protein/albumin ratio in ovarian cancer [4]The experience of immune checkpoint inhibitors in Chinese patients with metastatic melanoma: a retrospective case series [5]The Role of m6A Epigenetic Modification in the Treatment of Colorectal Cancer Immune Checkpoint Inhibitors. [6]治疗药物浓度监测在免疫检查点抑制剂应用中的研究进展 [7]Salmeterol/fluticasone treatment reduces circulating C-reactive protein level in patients with stable chronic obstructive pulmonary disease [8]特瑞普利单抗致stevens-johnson综合征 [9]The Role of m6A Epigenetic Modification in the Treatment of Colorectal Cancer Immune Checkpoint Inhibitors. [10]EZH1/2 alteration as a potential biomarker for immune checkpoint inhibitors across multiple cancer types

资源点击量：43377 今日访问量：0 总访问量：3120 更新日期：2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号